12 ms·
Antibiotic Breakthrough Ends 25-Year Discovery Drought
- refurb 12y agoThis is a bit of an odd article. The FDA has approved a number of different antibiotics over the past year. Most are not new mechanisms of action, but they are new products that have different profiles against different resistant bacteria. The other issue is that this is very early in development. I really hope it gets through trials, but there are graveyards full of promising antibiotics that failed.
- deeviant 12y agoMisses or hashed over many relevant facts. Claims of major scientific break-through, yet is describing something at a very early stage of development Nothing odd here, just the current state of scientific reporting.
- baldfat 12y agoThis in fact would be a different class. So it is a HUGE deal.
- astrodust 12y agoThey claim it's much harder for the bacteria to develop a resistance to, but that's very hard to prove without creating resistant bacteria. Let's not hand this one out like candy and end up back against the wall like we are now.
- refurb 12y agoThere are a number of different antibiotic class currently in development (in clinical trials already). This certainly isn't the "end of a drought".
- baldfat 12y agoThere has been exactly 2 new classes since 1962. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085877/ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085877/ Now if this actually works then yes great, and I hope it does.
- refurb 12y agoI think the reliance on new classes is a bit excessive. There are numerous new beta-lactams that have come out that are still in the same class, but have overcome (some of) the resistance issues. A new class would be great, but even different drugs from the same class would be great as well.
- baldfat 12y agoWhile there are new strains this would be a new class WHICH means AWESOME if it works out. Since this is so early I am not hoping for much. My son had cancer and he had a staph infection that was septic (AKA in his blood through out his body). Non-resistant = 95% cure rate resistant strain and if you have a compromised immune system less then 50% cure rate. Good news for cancer patients and glad to see it coming down the track.
- AceJohnny2 12y agoI had a friend die from a lung infection from a compromised immune system because of leukemia. Very glad to hear your son made it, and I echo your sentiment.
- NoMoreNicksLeft 12y ago> “It should be used, if it gets successfully developed, as broadly as possible, because it is exceptionally well-protected from resistance development,” said Kim Lewis, one of the study’s authors and a professor at Northeastern University in Boston. Lewis estimated that it may take more than 30 years for bacteria to become resistant to teixobactin. He is also a co-founder of NovoBiotic Pharmaceuticals LLC, which is developing the drug. I'd much rather get two or three more that all use different mechanisms, and use them as a cocktail. Let the bugs try to develop 3 different kinds of resistance at once.
- astrodust 12y agoConsidering how many bacteria are out there, and how frequently many of them multiply, even a one in a quadrillion chance of a mutation providing a resistance benefit is barely a speed-bump in evolutionary terms. Their "thirty year" claim is a best guess, but as this is entirely random, it could be three hundred, and it could be three. Remember there's about 10^14 bacterial cells in the average human body, ten times the number of human cells. Everyone's a big petri dish. If you killed all but one in a billion you'd still have a whole bunch left.
- Fomite 12y agoMultiple antibiotics often carry fairly serious medical risks. "Cured of your infection" is somewhat less heartening when we boxed your kidneys doing it.
- spanktar 12y agoI think the real meat of this article is here: "...strikes multiple targets, including cell walls...Since the lipid structures it attacks don’t evolve as quickly as frequently mutating proteins, it may take the bacteria longer than usual to develop a survival tactic." Proteins change often and quickly, but basic cell structures may take longer or never adapt. But I'm not a pathobiologist, I just play one on the Internet
- hga 12y agoSo do the β-Lactam antibiotics (e.g. penicillin), but that doesn't stop a host of unrelated resistance mechanisms: enzymes that directly attack it, mutations to the protein(s) that are necessary for entry into the bacteria, and probably the pumps that actively remove various antibiotics. Given that this was discovered from existing bacteria, there's a significant chance nature has already done the first and last of those. The middle mechanism is likely possible for any bacteria, if you have enough to start with (there's nothing I could find with Google in a minute to describe teixobactin's transport mechanism). In general there was a rule of thumb when I was doing microbiology of this exact nature (an antibiotic created by some strains of E. Coli), if you exposed a million bacteria cells to a generic antibiotic, 1 would would survive due to a mutation (a useful number in microbiology, likely dead meat in the body). Streptomycin was more effective, 1 in a billion. ADDED: it's implied by the Nature abstract that the researchers have tried this general approach, that they were not able to find spontaneous resistance mutations in a couple of the standard nasties. But extending on the above thesis, ecologically, there's a respectable chance some bacteria out there have developed defenses. It's a jungle out there, and e.g. in your gut, that's why fungi and bacteria developed antibiotics in the first place. They aren't expending resources just to allow us to kill the inconvenient ones.
- pcrh 12y agoFrom the Nature article, the claim that resistance to teixobactin is hard is based on an attempt by the authors to induce resistance by culturing S. aureus or M. tuberculosis in the presence of sub-lethal concentrations of teixobactin for 27 days and seeing if resistant clones evolved. They did not observe any. That doesn't mean it's impossible, though. Plasmids for example are a source of resistance that doesn't require mutations. Edit: deleted incorrect information about b-lactamase.
- TomAnthony 12y agoThey author's state "it should be used, if it gets successfully developed, as broadly as possible" - because they believe it is robust against bacteria developing resistance. Knowing nothing about this area... isn't this a bad idea because board use would increase the risk of resistance appearing and would mean those bacteria resistant to this would be extremely resistant to most other treatments aw well (given this drug has multiple modes of attack)?
- onezeno 12y agoThat was the statement by the guy trying to develop and sell it.
- balabaster 12y agoYeah, that was my first reaction too... Surely only using it in cases where other antibiotics hadn't proven successful would be a better approach so that you don't give bacteria much opportunity to become resistant. Broad use of antibiotics in cases where it wasn't needed is exactly how we got into this problem in the first place. Perhaps learning from history would be the most prudent approach.
- learc83 12y agoAntibiotic resistance has a fitness penalty. If we switch to this new antibiotic for long enough, bacteria may lose their resistance to our current antibiotics. I'm assuming their suggestion is to use this drug for the next 30 years, and by the time bacteria become resistant to it we can start using our old antibiotics again.
- Fomite 12y agoAntibiotic resistance does not necessarily have a strong fitness penalty - the spread of community-resistant MRSA is largely in environments where there isn't strong selective pressure against susceptible strains.
- tezza 12y agoI think some in depth academic research would be required to determine the optimal strategy. Intuitive strategies may not be as good as some counter-intuitive options. I'm not qualified to answer either way, I imagine several people could get PhDs finding out. It's too important to handle quickly
- dbcooper 12y agoThe Nature publication seems to be open access: http://www.nature.com/nature/journal/vaop/ncurrent/full/nature14098.html http://www.nature.com/nature/journal/vaop/ncurrent/full/natu... The Scientist has quite a nice write up: http://www.the-scientist.com/?articles.view/articleNo/41850/title/New-Antibiotic-from-Soil-Bacteria/ http://www.the-scientist.com/?articles.view/articleNo/41850/... Details on the cell culture device (open access): http://aem.asm.org/content/76/8/2445.full.pdf+html http://aem.asm.org/content/76/8/2445.full.pdf+html
- pcrh 12y agoThat device is a smart and clever approach! It will undoubtedly get used for many other applications.
- stevewilhelm 12y agoCompany's press release http://s831.us/1Dml4G5 http://s831.us/1Dml4G5
- kileywm 12y agoCan anyone clarify the core causes of antibiotic resistance over the last several decades? I've heard the following causes, but I cannot substantiate them: [1] Improper patient usage. Primarily, not taking the prescribed dosage long enough to eradicate all of the target bacterium, leaving (enough) survivors to meaningfully propagate their resistance. Typical to the "Hey I think my sinus infection is gone already! Adios remaining pills." [2] Improper targeting. A functional antibiotic used on the wrong type of bacterium, or even usage against viruses. Are there any others? Are my [1] and [2] debunked?
- Fomite 12y ago1. This is a major problem - patients start feeling better and discontinue therapy, which promotes resistance, save partially consumed prescriptions for "if this happens again", etc. 2. This is also a thing - broad spectrum antibiotics, difficulty in diagnosing, patients wanting something even if their infections are viral, etc. all lead to mistargeting of antibiotics for a number of reasons. Antimicrobial stewardship has become a major part of hospital infection control. 3. The widespread use of antibiotics in livestock. The agricultural use of antibiotics is staggering
- VLM 12y ago"patients wanting something even if their infections are viral" What the market needs is a placebo anti-biotic. One thats totally wasted by resistance so it won't hurt anything, and is reasonably cheap. Give it some nasty digestive system "effects" as a special gift to patients dumb enough to demand a pill against medical advice. Something that is, in fact, an antibiotic, so when they go home and look it up on wikipedia they don't freak out when they find out what a sucrose pill is. Maybe a homeopathic dose of it, so counter-reactions are rare and minimal.
- jrockway 12y ago"First, do no harm" is somewhat incompatible with dumb, demanding patients, unfortunately.
- tokenadult 12y agoA very interesting submission about the big medical news story of the day. The news suggests that we can all enjoy significant gains in finding effective treatments for dangerous infections. The era of antibiotics is probably not over yet, by a long way. As noted in another comment, the underlying Nature article is up on the World Wide Web, [after edit:] and now shared to all of us by a subscriber who posted a subscriber's-sharing link in this thread.[1] I searched for some other news stories about this preliminary research finding to link to others based on independent reporting as well as the authors' press release and the Nature article. I found a story in Financial Times[2] reporting, "Teixobactin quickly kills Gram-positive bacteria, which are prominent in discussions of antibiotic resistance, including Clostridium difficile, Mycobacterium tuberculosis and Staphylococcus aureus. "Neil Woodford, head of the antimicrobial resistance unit at Public Health England, commented: "'The rise in antibiotic resistance is a threat to modern healthcare as we know it, so this discovery could potentially help to bridge the ever increasing gap between infections and the medicines we have available to treat them.' "But Prof Woodford added: 'Although it is a step forward, this new discovery would not be suitable for treating infections caused by E. coli, Klebsiella or other Gram-negative bacteria.'" The Washington Post reports,[3] "But all good things must eventually come to an end. "'They didn't find resistance in a couple of simple tests, so it won’t happen in a minute, but there is no compound on this planet that bacteria will not develop resistance to,' Said Richard Novick, an NYU Langone Medical Center professor who wasn't involved in the study. 'But it would certainly happen more slowly with this one.' "And unfortunately, the drug's genius mechanism is also its biggest flaw. It can only target so-called gram-positive bacteria, like staph, strep, and TB, because they're unprotected once their cell wall starts to break down. Gram-negative bacteria like E. coli and the organisms that cause many sexually transmitted infections have an outer membrane that Teixobactin can't penetrate. That's probably a safety mechanism built-in by the gram-negative bacteria that created Teixobactin in the first place." That expert also comments that he would strictly limit application of this antibiotic at first to hospital settings, and that would be my policy recommendation too, to reduce the chance of producing selection pressure for resistant strains of bacteria. But this does look like it could be a big advance in clinical treatment of gram-positive bacterial infections resistant to other antibiotics. The reporting in The Scientist,[4] already linked by an earlier participant, includes a comment on the laboratory technique used to find the microorganism that produces this new antibiotic: "'This is a very clever technique,' added Robert Austin, a physicist at Princeton University who studies the evolution of microbes and was not involved in the current study. 'The bacteriology community needs to get away from culturing bacteria on agar plates, because this will not lead to new antibiotics.'" That's a familiar principle in science: look in a new place, and make new discoveries. The reporting in The Guardian[5] picks up on that idea in the words of another expert: "'What most excites me is the tantalising prospect that this discovery is just the tip of the iceberg,' said Mark Woolhouse, professor of infectious disease epidemiology at the University of Edinburgh. 'It may be that we will find more, perhaps many more, antibiotics using these latest techniques.'" It's very likely that there are more antibiotics yet to be discovered, because all microorganisms live in a world full of other microorganisms, and haphazard adaptation to that environment must have produced selection pressure for many microorganisms to produce natural chemicals ("antibiotics") that kill off other kinds of microorganisms. Putting those chemicals into human bodies applies human knowledge to take advantage of the variety of life that has arisen from evolution. [1] http://rdcu.be/bVbR http://rdcu.be/bVbR "A new antibiotic kills pathogens without detectable resistance" http://www.nature.com/nature/journal/vaop/ncurrent/full/nature14098.html http://www.nature.com/nature/journal/vaop/ncurrent/full/natu... DOI: 10.1038/nature14098 [2] http://www.ft.com/intl/cms/s/0/701a3c36-95be-11e4-a390-00144feabdc0.html#axzz3OAXfp1y4 http://www.ft.com/intl/cms/s/0/701a3c36-95be-11e4-a390-00144... [3] http://www.washingtonpost.com/news/speaking-of-science/wp/2015/01/07/new-class-of-antibiotic-found-in-dirt-could-prove-resistant-to-resistance/ http://www.washingtonpost.com/news/speaking-of-science/wp/20... [4] http://www.the-scientist.com/?articles.view/articleNo/41850/title/New-Antibiotic-from-Soil-Bacteria/ http://www.the-scientist.com/?articles.view/articleNo/41850/... [5] http://www.theguardian.com/science/2015/jan/07/antibiotic-drug-resistance-teixobactin http://www.theguardian.com/science/2015/jan/07/antibiotic-dr...
- betatim 12y agoFull text for free: http://rdcu.be/bVbR http://rdcu.be/bVbR This is a link to nature's new "share it for everyone to read if you have paid access to the article" version of 'open-access'. A new antibiotic kills pathogens without detectable resistance, Nature, January, 2015. DOI: 10.1038/nature14098
- ars 12y agoWhen they made roundup they expected plants would never be able to be resistant to it[1]. And in fact plants did not become resistant in the way they expected. Trouble is plants found a completely different way to resist roundup that no one expected. Their claim that bacteria would not become resistant to this antibiotic is rubbish. They do have the ability to determine that. If they actually want to know then deliberately try to (carefully) create resistant bacteria by continuously giving them low levels of antibiotic and slowly increasing it. [1] http://www.npr.org/blogs/thesalt/2012/03/11/148290731/why-monsanto-thought-weeds-would-never-defeat-roundup http://www.npr.org/blogs/thesalt/2012/03/11/148290731/why-mo...
- duskwuff 12y ago> If they actually want to know then deliberately try to (carefully) create resistant bacteria by continuously giving them low levels of antibiotic and slowly increasing it. That's precisely what they did while investigating teixobactin, and they didn't see any resistance develop: https://news.ycombinator.com/item?id=8853232 https://news.ycombinator.com/item?id=8853232
- ars 12y agoThat's quite impressive! Was there a control? i.e. same procedure, but with a different antibiotic?
- cowsandmilk 12y agoYes. They used ofloxacin as a control. Figure 2d in the paper. Kim Lewis, the senior author on this publication, is one of the world's foremost experts on antibiotic resistance. This isn't amateur hour.
- _craft 12y agoThe nytimes article mentions: "The research was paid for by the National Institutes of Health and the German government (some co-authors work at the University of Bonn). Northeastern University holds a patent on the method of producing drugs and licensed the patent to a private company, NovoBiotic Pharmaceuticals, in Cambridge, Mass., which owns the rights to any compounds produced. Dr. Lewis is a paid consultant to the company." If the research was paid for by the National Institutes of Health, why is the patent privately owned? This does not seem fair to taxpayers.
- deleted 12y ago[deleted]
- skosuri 12y agoThis is not only allowed, it's encouraged by legislation called the Bayh-Dole Act. The general thought is that there would be no incentive for anyone to do clinical trials on the drug, which can get quite expensive, if they don't have some protection for exclusive use. Many, if not most drugs proceed starting from academic research funded by governmental support.
- _craft 12y agoThanks for the informative response! Do you know how expensive clinical trials would be for this kind of drug?
- skosuri 12y ago$100M-500M gets thrown around [1] but it's hard to find good data. This might seem not too high, but many drugs fail, and often fail at the most costly step (phase III). So you have to be sure to factor that failure rate in. [1] http://www.manhattan-institute.org/html/fda_05.htm http://www.manhattan-institute.org/html/fda_05.htm
- refurb 12y agoDepends on what indication they are trying to get. A handy estimate is that a phase III trial costs $15K/person/year. If they aim for a 1000 person trial of 6 month duration, you're looking at $15M just for the phase 3 (I doubled it since they typically run two). However, that's a small trial.
- Gatsky 12y agoTheir experimental approach was interesting and hopefully will lead to more discoveries. I feel like this drug is already being overhyped however. It doesn't work for gram negative bacteria, which are responsible for most of the serious and scary multi drug resistant infections. Also, assuming it doesn't have weird toxicity in people, or unfavourable pharmacokinetics, the author's suggestion that we should give it to everyone is a bit cute, given that it will almost certainly cost north of $200 per day if it gets to market... Peptide antibiotics can have some issues. A recent new peptide antibiotic called Daptomycin [1] can't be used for pneumonia for example, because it is inhibited by pulmonary surfactant. [1] http://en.m.wikipedia.org/wiki/Daptomycin http://en.m.wikipedia.org/wiki/Daptomycin
- scarmig 12y agoIs $200/day a lot for a highly effective antibiotic? Genuine question--my experience is that a serious hospital stay racks up charges starting in the high five figures (and the sky's the limit), and if there's an antibiotic that's merely a couple thousand a day, it'd certainly be very cost effective.
- ajuc 12y ago> my experience is that a serious hospital stay racks up charges starting in the high five figures (and the sky's the limit) This is USA specific. Day in hospital in Poland costs around 100-400 USD (and that's for people without insurance, so for >95% of population it's free). It's probably worse quality, but still.. I don't understand how you get so outrageus prices for healthcare in USA.
- shanev 12y agoI think we'll be seeing more research like this in the future, where we develop drugs by mimicking nature instead of starting from scratch in the lab. Nature has had a few millions of years more to build and test things.
- trentmb 12y agoNature picks the least awful solution, not the best.
- nkozyra 12y agoBut least awful iterated thousands of times eventually leads to either "the best" or comparable to "the best." Not always the most efficient route, but largely dependable at scale.
- nkozyra 12y agoNature (at least in terms of natural antibiotic sources like fungi and bacteria) also has a relatively quick turnaround in terms of adaptation. Ultimately, developing antibiotics is a cat-and-mouse game, and eventually nanotech will render it archaic, but in the mean time the more we can do to be responsive and quick to adjust, the better, and that means new antibiotics. I do worry about this "30 year projection" and what that's based on. Is that a historical norm?
- shanev 12y agoI think nanotech will bring about it's own problems. What we should be doing is addressing the cause of antibiotic resistance in the first place, namely the overprescription of antibiotics, and their improper use in industrial farming.
- briantakita 12y agoI'm skeptical that this is a good thing given how the profit motive motivates people to "externalize" side effects; Environmental damage from antibacterial soaps, disrupting natural biological processes, disease-resistant bacteria, are a few effects. > Scientists have discovered an antibiotic capable of fighting infections that kill hundreds of thousands of people each year Given it's potential as a medicine, the media will hype it into public consciousness. Marketers & Entrepreneurs will use this social inertia to sell it in places where it is dangerous to use. The FDA has a history of revolving doors with big pharma & playing loose in pandering to corporate interests, at the expense of the public & environment. I'm merely presenting a minority view here on Hacker News. It's good to have all your t's crossed and i's dotted.
- Houshalter 12y agoAll of the comments are by armchair biologists about how the scientists are wrong and all bacteria strains will become resistant to it in 2 days. But anyways, if it is an issue, why can't we just require antibiotics be taken intravenously? The vast majority of bacteria exposed to antibiotics are in your digestive system and that is where resistance develops. Or at least that's how I understand it.
- robbiep 12y agoIV antibiotics generally mean hospital, which generally means severe life-threatening infection. Outpatient IV antibiotics are done but it's complicated and carry further risk of infection through having a line in situ for long periods of time. IV antibiotics do have an effect on gut bacteria as well, it's not as simple as just not giving oral; additionally (and, perhaps the crux of the issue) is that gut bacteria exposure to antibiotics is not how resistance develops; and certainly aren't the main problem. It is the more common infective agents that cause the problems - Gram positive organisms (Strep Viridians, Staph Aureus etc) that usually enter from cuts or abscesses and, in the immunocompromised, cause significant disability.
- Houshalter 12y ago>IV antibiotics do have an effect on gut bacteria as well, it's not as simple as just not giving oral; How so? And more importantly how much antibiotics make it to the gut, vs if you take it orally? I would guess it would be a lot less. >It is the more common infective agents that cause the problems I know that, but as I understand it the resistance first evolves in gut bacteria, then spreads through horizontal gene transfer. Wikipedia cites this as the main cause of antibiotic resistance: https://en.wikipedia.org/wiki/Horizontal_gene_transfer https://en.wikipedia.org/wiki/Horizontal_gene_transfer
- robbiep 12y ago> How so? And more importantly how much antibiotics make it to the gut, vs if you take it orally? I would guess it would be a lot less. I have no idea what figure or percentage it would be, but for most common antibiotics which end up distributed in total body water, there will be a component that leaks into the gut through capillary action; if it is metabolised in the liver then a proportion of it will end up in bile (if fat soluble) and then enter the gut that way; either itself or a metabolite of it - it would be impossible for me to quantify and likely depends on many many factors such as molecular weight, structure and a host of other features. Patients on IV antibiotics develop diarrhoea from IV antibiotics at a similar rate (from what I have experienced) to those on orals. hence it undoubtedly kills bacteria in a similar fashion. And we use IV antibiotics to kill bad infections of the gut. So whatever the mechanism, if I have elucidated it or simply done some hand-waving, it clearly affects it significantly. The only instance of antibiotic use that touches on what I feel you are pushing for is the use of oral vancomycin (It is almost always IV) for severe bacterial infections of the gut - we use it oral because it is not absorbed systemically (as opposed to other specifically oral antibiotics) so doesn't cause systemic effects. > then spreads through horizontal gene transfer. Sure. But if you look at how they tested this particular antibiotic for the ability to develop resistance, they exposed TB and Staph to sub-theraputic doses for 27 days, or (for Staph) or 810generations (assuming a rough rate of division somewhere around 40 min to 1 hr in ideal conditions). An epic number of cell divisions if you work it out (and I can't). The commonly accepted knowledge, as far as I understand it and as far as I have been taught it, whether or not bowel bacteria have a significant role to play or not, is that exposure of antibiotics to sub-lethal doses for long periods of time promote the survival of strains that have a competitive advantage against the agent in use, which over time allows the strain to survive in otherwise-lethal doses, and that gene becomes incorporated into a plasmid and then ends up spreading to every other organism capable of horizontal gene transfer. Anyway, I am at home and not going to see the next MD, PhD in Infectious Diseases until tomorrow but when I do I will ask him and reply here. So, check back in 24 hours if you're interested
- emmanueloga_ 12y agoThe mention of the "25 year discovery drought" made me think about this documentary I saw once about bacteriophages ("viruses that infect and replicate within bacteria") [1]. I don't remember the specific documentary but here is a wikipedia link [2] "Although extensively used and developed mainly in former Soviet Union countries circa 1920, the treatment is not approved in countries other than Russia and Georgia." 1: http://en.wikipedia.org/wiki/Bacteriophage http://en.wikipedia.org/wiki/Bacteriophage 2: http://en.wikipedia.org/wiki/Phage_therapy http://en.wikipedia.org/wiki/Phage_therapy
- jalada 12y agoHeadline should read: Zombie apocalypse averted for now.
- hga 12y agoDerek Lowe has his usual great analysis of this paper and the antibiotic: https://news.ycombinator.com/item?id=8862148 https://news.ycombinator.com/item?id=8862148